Genmab A/S (GNMSF)
447.55
0.00 (0.00%)
USD |
OTCM |
Oct 26, 16:00
Genmab Enterprise Value : 30.49B for Oct. 26, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 26, 2026 | 30.49B |
| October 23, 2026 | 30.49B |
| October 22, 2026 | 26.96B |
| October 21, 2026 | 26.96B |
| October 20, 2026 | 26.96B |
| October 19, 2026 | 26.34B |
| October 16, 2026 | 25.68B |
| October 15, 2026 | 25.68B |
| October 14, 2026 | 25.68B |
| October 13, 2026 | 25.68B |
| October 12, 2026 | 25.68B |
| October 09, 2026 | 25.68B |
| October 08, 2026 | 26.34B |
| October 07, 2026 | 26.34B |
| October 06, 2026 | 26.22B |
| October 05, 2026 | 27.47B |
| October 02, 2026 | 24.96B |
| October 01, 2026 | 24.96B |
| September 30, 2026 | 24.96B |
| September 29, 2026 | 24.96B |
| September 28, 2026 | 24.96B |
| September 25, 2026 | 24.84B |
| September 24, 2026 | 24.47B |
| September 23, 2026 | 23.99B |
| September 22, 2026 | 24.67B |
| Date | Value |
|---|---|
| September 21, 2026 | 24.25B |
| September 18, 2026 | 24.25B |
| September 17, 2026 | 24.25B |
| September 16, 2026 | 24.13B |
| September 15, 2026 | 24.01B |
| September 14, 2026 | 23.43B |
| September 11, 2026 | 23.43B |
| September 10, 2026 | 23.43B |
| September 09, 2026 | 23.43B |
| September 08, 2026 | 23.43B |
| September 04, 2026 | 23.43B |
| September 03, 2026 | 23.95B |
| September 02, 2026 | 23.95B |
| September 01, 2026 | 23.95B |
| August 31, 2026 | 23.95B |
| August 28, 2026 | 23.95B |
| August 27, 2026 | 23.95B |
| August 26, 2026 | 23.89B |
| August 25, 2026 | 23.89B |
| August 24, 2026 | 23.33B |
| August 21, 2026 | 23.89B |
| August 20, 2026 | 23.77B |
| August 19, 2026 | 22.87B |
| August 18, 2026 | 22.87B |
| August 17, 2026 | 22.87B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ascendis Pharma A/S | 15.69B |
| Zealand Pharma A/S | 161.11M |
| Bavarian Nordic A/S | 2.492B |
| Evaxion AS | 18.79M |
| ACADIA Pharmaceuticals, Inc. | 2.515B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 303.00M |
| Revenue (Quarterly) | 1.155B |
| Total Expenses (Quarterly) | 852.00M |
| EPS Diluted (Quarterly) | 4.91 |
| Gross Profit Margin (Quarterly) | 92.73% |
| Profit Margin (Quarterly) | 26.23% |
| Earnings Yield | 2.83% |
| Operating Earnings Yield | 4.68% |
| Normalized Earnings Yield | 3.450 |